FDA Staff Report Finds No Major Safety Concerns With Galleri Multicancer Blood Test

The Food and Drug Administration's Medical Devices Advisory Committee will soon vote on whether to recommend market authorization for the Galleri multi-cancer early detection test, a decision that will shape the agency's final ruling on the diagnostic. Ahead of that meeting, FDA reviewers released a briefing document on September 21, 2026, concluding that the agency's staff found "no major concerns" with the blood test developed by Grail.[1][3][4]

The Galleri test analyzes cell-free DNA in a single blood draw to identify methylation patterns associated with more than 50 types of cancer, many of which currently lack standard screening protocols. By detecting these epigenetic signatures, the diagnostic aims to identify malignancies before symptoms appear, potentially catching aggressive cancers at earlier, more treatable stages.[2][7]

In the executive summary, FDA reviewers noted that the clinical validation data submitted by Grail demonstrated a high specificity, meaning the test produces a low rate of false positives. The staff report confirmed that the accuracy metrics align with the manufacturer's claims, clearing a significant hurdle that often derails novel diagnostic tools during the regulatory review process.[1][4][5]

The release of the favorable briefing documents triggered an immediate market reaction, with Grail's stock price surging 34% in early trading on September 22, 2026. Investors interpreted the lack of red flags from FDA staff as a strong indicator that the advisory committee will ultimately recommend the test for broad clinical use.[3][6]

If authorized, Galleri is intended to be used alongside, rather than instead of, existing standard-of-care screening methods such as mammography, colonoscopy, and cervical cytology. The FDA staff emphasized this complementary role in their review, noting that the test's safety profile is acceptable provided it does not deter patients from undergoing established, guideline-recommended screenings.[1][2]

A central question for the upcoming advisory committee meeting will be how to manage the clinical workflow when a patient receives a positive Galleri result but subsequent imaging cannot locate a tumor. The FDA briefing documents acknowledged this challenge but did not classify it as a disqualifying safety risk, instead suggesting that post-market surveillance and clear clinician guidelines could mitigate the psychological and financial burden of unconfirmed positive signals.[1][5]

The regulatory submission relies heavily on data from clinical validation cohorts that tracked thousands of patients to measure the test's positive predictive value. The FDA staff review found the trial designs and statistical analyses to be sound, validating Grail's approach to quantifying the test's ability to accurately predict the tissue of origin for detected cancers.[1][2][3]

The advisory committee will now weigh this staff assessment alongside independent expert testimony and public comments. While the FDA is not bound by the advisory committee's upcoming vote, it typically follows the panel's recommendations when making its final authorization decisions, setting the stage for a potential commercial rollout later in 2026 or early 2027.[1][2][6]